Hepatitis B reactivation in people living with HIV and isolated anti‐ HBc receiving tenofovir‐sparing dual antiretroviral therapy

Documenti analoghi

• Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study
  di: C. Busca‐Arenzana, et al.
  Pubblicazione: (2024)
• Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy
  di: Vincenzo Malagnino, et al.
  Pubblicazione: (2024)
• Availability and stock‐outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda
  di: Tom G. Jacobs, et al.
  Pubblicazione: (2024)
• Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies
  di: C. Martorell, et al.
  Pubblicazione: (2025)
• Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV‐1 and end‐stage kidney disease on chronic haemodialysis
  di: Joseph J. Eron, et al.
  Pubblicazione: (2024)